Bladder Cancer
Conditions
Keywords
recurrence, 5-alpha-reductase inhibitor, Low-grade bladder cancer
Brief summary
Low grade non-muscle-invasive bladder cancer (NMIBC) often recurs after treatment, requiring repeated surgeries, especially in older patients. These recurrences can cause complications, reduce quality of life, and increase healthcare costs. Currently, there is no well-tolerated preventive treatment routinely used for patients with low-risk disease. This study will evaluate whether dutasteride, an oral medication that blocks androgen activity, can reduce the risk of bladder cancer recurrence. Dutasteride is generally well tolerated and easy to take. The study will also assess its safety in women. The goal of this study is to determine whether dutasteride can provide a simple and effective way to prevent recurrences of low grade non-muscle invasive bladder cancer.
Detailed description
The study will therefore include two separate cohorts of men (n=70) and women (n=25). After the screening phase, eligible male and female patients who provide informed consent will receive dutasteride at a dose of 0.5 mg once daily for the duration of the study. All participants will follow the same treatment regimen. Treatment will be continued until tumor recurrence or for up to two years in the absence of recurrence. Prior data suggests a long-term mecanism of action of dutasteride in preventing tumor recurrences. Therefore, in the event of tumor recurrence, patients will be offered the option to continue dutasteride treatment for a total duration of up to two years. The decision to continue or discontinue treatment, as well as the reasons for this decision, will be documented. Regarding analyses, the male cohort is designed to provide the first prospective data on efficacy; data will be compared to a historical control cohort, while also collecting adherence and safety data specific to men with low grade NMIBC. The parallel female cohort is primarily intended to assess feasibility of recruitment and safety. In the published literature and our own institutional data, women represent approximately 25% of patients with low grade NMIBC. Recruitment of female patients is therefore more challenging, compounded in part by the limited safety data available and the absence of demonstrated urinary benefits. Consequently, this cohort aims to determine whether inclusion of women in a subsequent phase 3 study will be feasible and safe.
Interventions
Dutasteride 0.5 mg orally once daily. Treatment begins after enrollment and continues for 2 years or until tumor recurrence. Patients may opt to continue treatment after recurrence for a total of 2 years.
Sponsors
Paul Toren
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The study will therefore include two separate cohorts of men (n=70) and women (n=25).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged 18 or greater; * Patients with histologically confirmed low grade non-muscle invasive urothelial carcinoma. Patients with any mix of low- and high-grade urothelial carcinoma remain eligible given the frequent histological heterogeneity and the presence of a low grade component; * Patients have not been recommended for a course of intravesical BCG or chemotherapy induction treatment by their urologist; * Male patients with partners of child-bearing potential must agree to 2 acceptable forms of birth control and be continued for at least 6 months after study drug is discontinued.
Exclusion criteria
* Patients who are scheduled to receive BCG therapy or have received BCG therapy within the last 5 years will be ineligible for enrollment. * Patients who are scheduled to receive intravesical chemotherapy or have received an induction course of intravesical chemotherapy within the last 5 years will be ineligible for enrollment. Patients who received a single, post-operative (\<24h) intravesical chemotherapy (e.g. gemcitabine, epirubicin or mitomycin C) dose are eligible. * Patients with clinical hypogonadism, those on androgen replacement therapy, or those with prostate cancer or other diseases treated with various forms of hormonal therapy will be ineligible for study enrollment. * Patients receiving 5-alpha-reductase inhibitors within the last 2 years are ineligible for enrollment. * Patients with a history of allergy or severe adverse reaction to finasteride or dutasteride are ineligible for enrollment. * Patients with a history of liver disease whose hepatic enzymes, alkaline phosphatase or bilirubin are greater than twice the upper limit of normal will be ineligible. Nonetheless, patients with Gilbert's disease may be accepted in the study. * Patients with multiple hospital admissions for heart failure within the previous 12 months or who have unstable cardiovascular status will be ineligible for enrolment. * Female patients with child-bearing potential are ineligible for enrollment, which is defined as any female under 50 years of age. Exceptions to this age limit may be permitted on a case-by-case basis by the Principal Investigator, based on documented confirmation that there is no child-bearing potential (such as a female without a uterus). * Patients receiving chronic treatment with potent CYP3A4 inhibitors, including but not limited to ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, troleandomycine, or ciprofloxacin, are ineligible for participation in the study. Occasional use of CYP3A4 inhibitors such as ciprofloxacin for an infection is not prohibited.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of NMIBC recurrences in patients treated with dutasteride | From enrolment until first recurrence or 4 years of extended follow-up, whichever occurs first | To facilitate historical comparisons, a pathologic definition of recurrence is selected. Thus, investigators will be mandated to perform confirmatory biopsies or surgical resection of recurrences. For the female population, recruitment will be compared to the male population based on the established 1:3 ratio of female to male patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to surgery | From enrolment until surgery for suspected recurrence of bladder cancer or 4 years of extended follow-up, whichever occurs first | Time to surgery under general anesthesia: time from enrolment until surgery for suspected recurrence of bladder cancer |
| Incidence of tumour progression | From enrolment until first progression or 4 years of extended follow-up, whichever occurs first | The proportion of patients who experienced tumor progression at the end of follow-up. Progression is defined as a recurrence with an increase in tumour grade to high grade, or an increase in stage, or the new presence of CIS. |
| Number of tumour recurrences: | From enrolment until first recurrence or 4 years of extended follow-up, whichever occurs first | This is defined as the number of recurrences per patient. |
| Number of tumours at recurrence | From enrolment until first recurrence or 4 years of extended follow-up, whichever occurs first | This is defined as the number of tumors at the recurrence. This information is based on cystoscopic findings at time of the cystoscopy preceding surgical resection or the cystoscopy without anesthesia at which the biopsy indicating recurrence was taken. |
| Concordance of cystoscopic recurrence with pathologic recurrence | From enrolment until 4 years of extended follow-up, whichever occurs first | The proportion of suspected pathologic recurrences which were confirmed urothelial carcinoma on pathologic analysis |
| Quality of life assessed by the European Organisation for Research and Treatment of Cancer(EORTC) Quality of Life Questionnaire (QLQ) non-muscle invasive bladder cancer questionnaire(NMIBC) module 24 | From enrolment to 24 months (end of treatment) | Quality of life will be evaluated with the EORTC QLQ-NMIBC24 questionnaire as a global score (linear transformation to 0-100, higher=better). |
| Urinary symptoms assessed by Bladder Utility Symptom Score (BUSS) | From enrollment until 2 years (end of treatment) | Urinary symptoms will be evaluated using BUSS questionnaire (0-100, higher=better) |
| Urinary symptoms assessed by the Internation Prostate Symptom Score (IPSS) questionnaire | From enrollment until 2 years (end of treatment) | Urinary symptoms will be evaluated using the IPSS(0-35, mild (0-7), moderate (8-19), or severe (20-35)) questionnaire among male patients. |
Countries
Canada
Contacts
CONTACTPaul Toren Principal Investigator, MD
CONTACTMarjorie Besançon, PhD
Outcome results
None listed